
|Articles|August 28, 2008
Medco and FDA to collaborate on pharmacogenomics
The groups have signed a two-year agreement.
Advertisement
Pharmacy benefit manager Medco and the Food and Drug Administration have signed a two-year agreement to develop pharmacogenomics research projects to study genetic testing and the effect of genetics on prescription drugs.
The research will initially focus on the blood-thinner warfarin but may later include oncology and virology. Medco and the FDA hope the research will help health professionals better select medications and dosages for individual patients.
To see more Daily News articles,
To go to the Drug Topics homepage,
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Study Identifies Patients at Risk for Severe COVID-19 Post-Vaccination
2
Model Finds Weight Regain After Stopping Semaglutide or Tirzepatide
3
Investigational Oral AD109 Reduces Sleep Apnea Severity by 44%
4
Zepbound Lowers Health Care Costs in Older Adults With Obesity
5






































